GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (FRA:V9Z) » Definitions » Cyclically Adjusted Price-to-FCF

Aceragen (FRA:V9Z) Cyclically Adjusted Price-to-FCF : (As of May. 30, 2024)


View and export this data going back to . Start your Free Trial

What is Aceragen Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aceragen Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Aceragen's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Cyclically Adjusted Price-to-FCF Chart

Aceragen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aceragen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aceragen's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Aceragen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aceragen's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aceragen's Cyclically Adjusted Price-to-FCF falls into.



Aceragen Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Aceragen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Aceragen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-1.235/127.3478*127.3478
=-1.235

Current CPI (Mar. 2023) = 127.3478.

Aceragen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 -11.661 98.518 -15.073
201309 -10.399 98.790 -13.405
201312 -6.924 98.326 -8.968
201403 -9.848 99.695 -12.580
201406 -8.054 100.560 -10.200
201409 -10.494 100.428 -13.307
201412 -11.301 99.070 -14.527
201503 -15.317 99.621 -19.580
201506 -10.399 100.684 -13.153
201509 -12.349 100.392 -15.665
201512 -8.978 99.792 -11.457
201603 -13.033 100.470 -16.520
201606 -9.815 101.688 -12.292
201609 -10.514 101.861 -13.145
201612 4.147 101.863 5.185
201703 -15.079 102.862 -18.668
201706 -11.580 103.349 -14.269
201709 -9.065 104.136 -11.086
201712 -7.352 104.011 -9.002
201803 -8.183 105.290 -9.897
201806 -7.473 106.317 -8.951
201809 -6.336 106.507 -7.576
201812 -6.305 105.998 -7.575
201903 -7.264 107.251 -8.625
201906 -5.276 108.070 -6.217
201909 -5.801 108.329 -6.819
201912 -5.413 108.420 -6.358
202003 -5.012 108.902 -5.861
202006 -3.755 108.767 -4.396
202009 -2.917 109.815 -3.383
202012 -2.919 109.897 -3.383
202103 -1.930 111.754 -2.199
202106 -1.769 114.631 -1.965
202109 -1.287 115.734 -1.416
202112 -1.152 117.630 -1.247
202203 -1.333 121.301 -1.399
202206 -1.070 125.017 -1.090
202209 -1.031 125.227 -1.048
202212 -3.400 125.222 -3.458
202303 -1.235 127.348 -1.235

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aceragen  (FRA:V9Z) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Aceragen Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Aceragen's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aceragen (FRA:V9Z) Business Description

Industry
Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Aceragen (FRA:V9Z) Headlines

No Headlines